Researchers who examined records from the Tennessee Medicaid program found that those who take newer "atypical" medicines for schizophrenia and other psychiatric disorders had double the risk of heart attack compared with nonusers. Among the drugs cited are AstraZeneca's Seroquel, Eli Lilly and Co.'s Zyprexa and Johnson & Johnson's Risperdal.

Full Story:

Related Summaries